



# Perspective on Broad-Acting Clinical Physiological Effects of Photobiomodulation

Steven Shanks and Gerry Leisman

## Abstract

Research into photobiomodulation reveals beneficial effects of light therapy for a rapidly expanding list of medical conditions and illnesses. Although it has become more widely accepted by the mainstream medicine, the effects and mechanisms of action appear to be poorly understood. The therapeutic benefits of photobiomodulation using low-energy red lasers extend far beyond superficial applications, with a well-described physics allowing an understanding of how red lasers of certain optimum intensities may cross the cranium. We now have a model for explaining potential therapeutics for applications in functional neurology that include stroke, traumatic brain injury, and neurodegenerative conditions in addition to the currently approved functions in lipolysis, in onychomycosis treatment, and in pain management.

## Keywords

Cold laser · Laser therapy · Lipolysis · Neurodegeneration · Onychomycosis · Pain ·

Photobiomodulation · Photobiostimulation · Stroke

## 1 Introduction

Photobiomodulation or low-level laser therapy, low-intensity laser therapy, low-power laser therapy, cold laser, soft-laser, or photobiostimulation has been studied for over 50 years (Anders et al. 2015; Mester and Jászszági-Nagy 1971), with new clinical applications of light therapies growing exponentially. Unfortunately, this has resulted in a growing confusion about the clinical effectiveness of this technology due to the diverse assortment of lasers and light-emitting diode (LED) devices employing different light wavelengths, each purportedly treating conditions from hair loss (Avci et al. 2014) to cancer and neurodegenerative disease (Santana-Blank et al. 2016). To alleviate some of this confusion, “photobiomodulation” (PBM) has recently been added to the Medical Subject Headings of the National Library of Medicine thesaurus for PubMed indexing. The

S. Shanks  
Erchonia Corporation, Melbourne, FL, USA

G. Leisman (✉)  
Faculty of Health Sciences, University of Haifa, Haifa,  
Israel

National Institute for Brain & Rehabilitation Sciences,  
Nazareth, Israel  
e-mail: [g.leisman@alumni.manchester.ac.uk](mailto:g.leisman@alumni.manchester.ac.uk)

purpose of introducing a new term was to distinguish the PBM from other light-based devices that rely on thermal effects for some or all of their mechanisms of action.

Among the characteristics of PBM, including wavelength, power, and energy density, an emphasis has been placed on the ability of light to penetrate tissue (Hamblin 2017). Although PBM is well established as a beneficial treatment for numerous conditions, skepticism exists among those who think that light therapy, and particularly low-energy red lasers, can only be used to treat superficial conditions due to non-penetration of light energy in the body and bone. Far-red and near-infrared light waves do penetrate tissue to some extent. However, red lasers are capable of producing beneficial effects extending beyond treatment of superficial conditions (Grover et al. 2017; Maksimovich 2016; DeTaboada et al. 2006). It is apparent that the mode of therapeutic action of PBM is as complex as the pharmacokinetics of many medications. In the editorial in *Photomedicine and Laser Surgery*, Tiina Karu (2013) has asked a question: “Is it time to consider photobiomodulation as a drug equivalent?” She cited the use of PBM for treating a wide range of disorders including Parkinson’s (Shaw et al. 2010) oral mucositis (Bjordal et al. 2011), peripheral nerve damage (Moges et al. 2011), ischemic tissue injury (Lapchak 2010), and other disorders (Santana-Blank et al. 2016).

The objective of this review is to provide perspective on the physiologically modifying properties of PBM, with potential application extending far beyond superficial applications including the evolving applications in functional neurology.

---

## 2 Photobiomodulation Effects

PBM employs non-ionizing light, including lasers, light-emitting diodes, or broadband light in the visible red (600–700 nm) and near-infrared (780–1100 nm) spectra to achieve therapeutic effects (de Freitas and Hamblin 2016). PBM is a nonthermal process beginning when a

chromophore molecule is exposed to a suitable wavelength of light. Chromophores are responsible for the color associated with biological compounds such as hemoglobin, myoglobin, and cytochromes (Cotler et al. 2015). When a chromophore absorbs a photon of light, an electron transits to an excited state. A common target chromophore for PBM is the iron- and copper-containing enzyme cytochrome C oxidase in the mitochondrial respiratory chain, which absorbs light in the near-infrared spectrum (Avci et al. 2013; Karu and Afanasyeva 1995). The physiologic effects of PBM occur when photons dissociate the inhibitory signaling molecule of nitric oxide (NO), from cytochrome C oxidase, increasing the electron transport, mitochondrial membrane potentials, and the production of mitochondrial products such as ATP, NADH, RNA, and cellular respiration (Wang et al. 2016; de Freitas and Hamblin 2016).

Other effects include increases in the antioxidant enzyme activity, such as catalase and superoxide dismutase (Martins et al. 2016) or mitochondrial NO synthase, release of NO, also a potent vasodilator (Adamskaya et al. 2011), and the production of reactive oxygen species (ROS). ROS play an important role in cell signaling, cell cycle progression regulation, enzyme activation, and nucleic acid and protein synthesis (Holmström and Finkel 2014). ROS also activate transcription factors, leading to cellular proliferation, migration, and production of cytokines and growth factors (Farivar et al. 2014). Alternatively, light-sensitive ion channels can be opened to permit calcium ion entry into the cell.

Based on these complex characteristics, PBM possesses physiologically modifying properties associated with specific light characteristics, such as wavelength and irradiance, varied by exposure parameters, such as energy density, irradiation duration, and treatment frequency. Similarly to pharmacological agents, BPM displays a biphasic dose-response described by the Arndt-Schulz law (Huang et al. 2009). Increasing the PBM dose, based on exposure time or energy density, increases the response to a maximum effect, after which a further exposure increase results in decreased response or bioinhibition.

The biphasic dose-response of BPM has been demonstrated in *in vitro* (Solmaz et al. 2017; Hawkins and Abrahamse 2006) and in *in vivo* studies (de Lima et al. 2014; Hsieh et al. 2014; Rojas and Gonzalez-Lima 2013). These properties of BPM are sharply contrasted with infrared radiation (780–3000 nm), which heats tissues, resulting in physical changes.

PBM has been demonstrated to be beneficial for treating chronic joint disorders (Bjordal et al. 2003), musculoskeletal (Cotler et al. 2015), chronic low back (Huang et al. 2015) and neck pain (Gross et al. 2013; Chow et al. 2009), herniated disks (Takahashi et al. 2012), adhesive capsulitis (Ip and Fu 2015), and in wound healing (Aragona et al. 2017; Heidari et al. 2017; Yadav and Gupta 2017; Arany 2016; Kuffler 2016). PBM has even been determined to be promising for treating psychiatric and neurodegenerative disorders (Berman et al. 2017; Salehpour and Rasta 2017; Cassano et al. 2016; Hamblin 2016).

To date, clinical trials have demonstrated the therapeutic effects of PBM leading to the US-FDA clearance of devices for body sculpting (Roche et al. 2017; Thornfeldt et al. 2016; Suarez et al. 2014; McRae and Boris 2013; Jackson et al. 2012; Nestor et al. 2012; Jackson et al. 2009), cellulite (Jackson et al. 2013), pain (Roche et al. 2016), and, most recently, onychomycosis (Zang et al. 2017). There have been no reports of treatment-related adverse events.

---

## 3 Potential Clinical Applications

### 3.1 Lipolysis

Activation of cytochrome C oxidase triggers cellular events including an increase in ATP synthesis, with upregulation of cAMP and cytoplasmic lipase activation. Activated lipase breaks down intracellular triglycerides into fatty acids and glycerol (Karu and Afanasyeva 1995). An additional effect of cytochrome C oxidase activation

is a transient formation of pores in the cell membrane of adipocytes, allowing the newly formed fatty acids and glycerol to pass into the extracellular space (Solarte et al. 2003). Electron microscopic images have demonstrated pore formation in the cell membranes of adipose cells exposed to low-level laser light. Upon entering the extracellular space, lipids released following PBM treatment are transported to lymph nodes, where lysosomal acid lipase hydrolyzes the released triglycerides to generate non-esterified free fatty acids (Neira et al. 2002). Alternatively, released lipids may be transported via the lymphatic system to the liver where they undergo normal fatty acid oxidation. Clinically, the use of PBM has been associated with decreased plasma triglycerides and cholesterol (Jackson et al. 2010; Rushdi 2010). Importantly, PBM does not result in necrosis, the endocrine function of adipose tissue is preserved (Poulos et al. 2010), and it prevents inflammatory effects of high-intensity focused ultrasound (Burks et al. 2011; Biermann et al. 2010) and cryolipolysis (Avram and Harry 2009).

### 3.2 Pain

A well-controlled trial has assessed PBM efficacy for treating chronic shoulder and neck pain and improving the upper body range of motion (ROM) (Roche et al. 2016). Participants received PBM using a diode laser emitting a divergent 635 nm (red) laser light (energy output of 1 mW) or sham treatment. After 48 h, 28 out of the 43 PBM-treated subjects (65.1%) demonstrated a greater than 30% improvement in pain scores vs. six (11.6%) in the sham-treated group.

The mechanism whereby PBM decreases pain is unknown (Hamblin 2017; Holanda et al. 2017). The analgesic and anti-inflammatory effects of PBM are associated with increased antioxidant glutathione and decreased expression of P2X3

receptor subunits in C- and A $\delta$ -fiber afferent neurons (Janzadeh et al. 2016), significant reductions in cyclooxygenase-2 (COX-2) mRNA (Prianti et al. 2014), activation of endogenous opioids (Pereira et al. 2017), reductions in pro-inflammatory cytokines and glutamate, increases in endogenous analgesic prostatic acid phosphatase (Pires de Sousa et al. 2016), and the expression of bradykinin receptors (de Oliveira et al. 2017).

### 3.3 Onychomycosis

Zang et al. (2017) have reported on the use of PBM for treating onychomycosis. Fifty affected toenails were treated for 12 min weekly for 2 or 4 weeks with a 635/405 nm dual-diode laser device. Most treated toenails (67%) achieved individual treatment success. The extent of clearing at the nail baseline increased by a mean of  $4.8 \pm 5.2$ (SD) mm after 6 months. Nearly all treated toenails (89%) demonstrated an increase in the area of clear nails over the 6-month study period. Based on the safety and efficacy, this nonthermal laser PBM device received FDA 510 (k) market clearance for a temporary nail clearing in patients with onychomycosis caused by dermatophytes or yeasts.

PBM also exhibits antimicrobial effects on biofilms formed by *Streptococcus mutans* and *Candida albicans* (Basso et al. 2011) and activity against *C. albicans* cultures (Maver-Biscanin and Mravak-Stipetic 2005). It also is effective against oral *C. albicans* infections in mice and humans in vivo (Seyedmousavi et al. 2014; Scwingel et al. 2012) and against the fungus *Paracoccidioides brasiliensis* in both in vitro and in vivo (Burger et al. 2015).

The mechanisms of antifungal effect of PBM are unclear. Exposure of cytochrome C oxidase in the mitochondrial respiratory chain to suitable wavelength of light results in increased production of mitochondrial ATP, NADH, and RNA and increased cellular respiration (de Freitas and Hamblin 2016; Wang et al. 2015; Chung et al. 2012). Consistent with these effects, neutrophils from PBM-treated mice become more

metabolically active and have higher fungicidal activity (Burger et al. 2015). When stimulated by PBM in vitro, human neutrophils show a greater production of ROS and increased fungicidal capacity against *C. albicans* (Cerqueira et al. 2016).

In contrast, thermal lasers used for treating onychomycosis emit light in the near-infrared spectrum (780–3000 nm) and exert their effect by simply heating the target tissue (Nenoff et al. 2014). In vitro studies have demonstrated a thermal killing effect on fungal mycelia when treatment temperatures exceed 50 °C (Carney et al. 2013; Paasch et al. 2013). The mean peak temperatures associated with an 808 nm laser is 74.1–112.4 °C and that of a 980 nm laser is 45.8–53.5 °C (Paasch et al. 2014). Consequently, the use of thermal lasers has been associated with moderate pain or burning sensations (Helou et al. 2016; Moon et al. 2014; Noguchi et al. 2013) and darkening under the nail (Lu et al. 2016). Discomfort is minimized by using a pulsed-wave laser instead of continuous-wave laser (Anderson and Parrish 1983).

---

## 4 Functional Neurological Applications

### 4.1 Photobiomodulation and the Cranial Vault

A significant literature exists on the ability of PBM to penetrate the skull in both diagnostic and therapeutic applications. Low-energy laser passes the skull and a therapeutic effect likely exists. Low-energy laser systems employ the so-called quantum optical induced transparency (QIT) effect (Weis et al. 2010; Harris et al. 1990). Quantum interference in the amplitude of optical transitions in atomic media can lead to strong modification in optical properties. This effect, electromagnetically induced transparency, controls optical properties of dense media and can enhance transparency contrast by a factor of five (Scherman et al. 2012). Therefore, the skull, spine, or joints can be penetrated even with moderate intensity light. Due to the QIT effect, the

radiation should reach deep tissue layers in muscles, connective tissue, and even bone, enabling noninvasive transcranial treatments for neurodegenerative diseases, stroke, or traumatic brain injury (TBI) (Tedford et al. 2015; Stemer et al. 2010; Oron et al. 2006). Litscher and Litscher (2013) have reported that laser emission in the yellow band of the light spectrum could penetrate the human cranium making PBM a promising option for treating neurodegeneration or stroke, TBI, and other neurologically based conditions. A central constraint controlling the depth of penetration of laser light past the cranium is wavelength. Both absorption and scattering coefficients of living tissue are greater at lesser wavelengths with near-infrared light penetrating more deeply than red light. It also is argued that pulsed-wave lasers penetrate more deeply into tissue than continuous-wave lasers with the same average energy power.

Let us suppose that at a wavelength of 810 nm, the depth of tissue at which the laser intensity is reduced to 10% of its value at the skin surface is 1 cm. A laser, with a power density (irradiance) of 100 mW/cm<sup>2</sup> at the skin, would have a power density of 10 mW/cm<sup>2</sup> 1 cm below the skin and of 1 mW/cm<sup>2</sup> 2 cm below the skin. Now, suppose that a threshold power density, a minimum number of photons *per unit area per unit time*, at the target tissue is necessary to have a biological effect and that this value is 10 mW/cm<sup>2</sup>. The effective penetration depth of continuous-wave laser may be, say, 1 cm. By contrast, let us consider a pulsed-wave laser with a 10 ms pulse duration and frequency of 1 Hz (direct current (DC) = 1 Hz × 0.010 s = 0.010) and the same average energy power. The peak power and power densities are now 100 times higher (peak power = average power/DC = average power × 100). With a peak power density of 10 W/cm<sup>2</sup> at the skin, the tissue depth, at which this peak power density attenuates to the threshold level of 10 mW/cm<sup>2</sup>, is now 3 cm rather than 1 cm in the continuous-wave mode. However, it should be taken into consideration that the laser is on only for 1% of the time, so that the total fluence delivered to 3 cm depth in the pulse-waved mode


is 100 times less than that delivered to 1 cm depth in the continuous mode.

The use of PBM to treat diseases, disorders, and injuries of the brain requires a detailed understanding of the nature of light propagation through tissues including the scalp, skull, meninges, and brain. Tedford et al. (2015) have investigated light penetration gradients in the human cadaver brains using a transcranial laser system with a wavelength of 808 nm and wavelength dependence of light scatter and absorbance in intraparenchymal brain tissue using 660, 808, and 940 nm. Those authors demonstrate that the 808 nm wavelength light has a superior brain tissue penetration.

## 4.2 Photobiomodulation (PBM) Application for Neurodegenerative Diseases

Peptide fibrillization is associated with the creation of amyloid fibers in Parkinson's and Alzheimer's diseases (Luo et al. 2000). Hanczyc et al. (2012) have shown that amyloids demonstrate robust nonlinear optical absorption that is not extant in native non-fibrillized proteins. Pérez-Moreno et al. (2008) have found that lysozyme  $\beta$ -amyloids, insulin, and  $\alpha$ -synuclein display two-, three-, or multiphoton absorption processes, depending on the wavelength of light. Olesiak-Banska et al. (2012) have suggested that a heightened multiphoton absorption is the outcome of a mechanism comprising dipolar through-space pairing between excited states of aromatic amino acids compacted in fibrous assemblies (Figs. 1 and 2).

Moro et al. (2014) have investigated neuroprotection offered by PBM in the mouse model. Mice were treated with PBM 20 times over 4 weeks and Alzheimer's disease-related histochemical markers were examined in the neocortex and hippocampus. Those authors show that PBM treatment decreases neurofibrillary tangles, hyperphosphorylated tau protein, and oxidative stress markers, as well as restores cytochrome C oxidase, which suggests that it may potentially be



**Fig. 1** (a) Z-scan example measurement of nonlinear refractive index and (b) nonlinear absorption coefficient of amyloid sample. Femtosecond Z-scan using  $100 \text{ GW/cm}^2$  irradiation at 930 nm with closed (a) and open openings. (b) Amyloid fibrils (squares) are compared

to native protein (circles). Theoretical fits are shown for two-photon absorption (2PA, light-gray solid curve), three-photon absorption (3PA, dark-gray solid curve), and five-photon absorption (5PA, red solid curve) (With permission from Olesiak-Banska et al. 2012)


an effective, minimally invasive intervention for progressive cerebral degeneration.

As downregulation of hippocampal brain-derived neurotrophic factor (BDNF), necessary for neuronal survival and dendritic sprouting, occurs in early Alzheimer's disease, BDNF upregulation may provide a mechanism to save dendritic atrophy in the disease course. Meng et al. (2013) have found that PBM reverses a decline in dendritic atrophy and in the number of neurons by means of BDNF upregulation. The PBM, through modulation of the transcription factor cAMP response element-binding protein (CREB), increases BDNF, mRNA, protein expression, as well as dendrite growth (dendritic

spine length, density, and branching in hippocampal neurons).

### 4.3 Stroke

In an early study with transcranial-PBM (T-BPM) for stroke treatment in the rat model, Zhang et al. (1997) have obtained significant results. T-BPM at 808 nm, a previously alluded to important wavelength, significantly improves recovery 3 weeks after ischemic stroke. The regimen included one treatment on the contra-lesional side (power density:  $7.5 \text{ mW/cm}^2$ ) 24 h post-stroke, with a good result in terms of neurogenesis stimulation.



**Fig. 2** Wavelength dependence of exponent  $n$  (the apparent number of photons taking part in the nonlinear absorption process) defined from  $dI/dz = -kI^n$  with  $z$  denoting propagation distance  $I$  denoting light intensity. Steps

marked with vertical arrows: below 625 nm, two-photon absorption and below 850 nm, three-photon absorption (From Olesiak-Banska et al. 2012 with permission)

A study in embolized rabbits has shown a direct relationship between cortical fluence (energy density,  $J/cm^2$ ) and cortical ATP (Lapchak and DeTaboada 2010). Five minutes following embolization, rabbits received a 2-min PBM using 808 nm laser on the skin surface. Continuous-wave (CW) PBM ( $7.5\text{ mW}/cm^2$ ,  $0.9\text{ J}/cm^2$ ) produced a 41% increase in cortical ATP. A 100 Hz pulse wave (PW) PBM ( $37.5\text{ mW}/cm^2$ ,  $4.5\text{ J}/cm^2$ ) produced a 157% increase in cortical ATP. The authors suggest that even a greater improvement potential might be achievable by treatment length and mode (PW, at approximately 100 Hz) optimization.

T-BPM has been shown to significantly improve outcome in human stroke patients, when administered 18 h post-stroke, over the entire head surface, regardless of stroke localization (Lampl et al. 2007). Significant improvements are observed in the moderate and

moderate–severe patients, but not in severe stroke patients (Zivin et al. 2009).

#### 4.4 Traumatic Brain Injury (TBI)

Mild traumatic brain injury (mTBI) patients demonstrate cognitive and memory difficulties for at least 6 months or later after an episode. There is a significant requirement for effectual methods to foster cognitive recovery (Cicerone et al. 2006). mTBI from single and multiple events has been the most recurrent injury experienced by military personnel in the Operation Enduring Freedom and Operation Iraqi Freedom (Hoge et al. 2008). Diffuse axonal injury is frequently evidenced in frontotemporal and anterior-corona-radiata regions (Niogi et al. 2008; Taber et al. 2006). Cognitive impairments result from tissue injury in the prefrontal and

frontal cortical regions and anterior cingulate gyrus within the frontal lobes. PBM has been applied in animal TBI models (Oron et al. 2007). Mice were subjected to closed head injury. Five days later, motor behavior was significantly better in the PBM-treated group. Twenty-eight days post-injury, the mean lesion size in the laser-treated group was significantly smaller than in controls. The PBM has also had positive effects in other studies (Wu et al. 2012; Moreira et al. 2009). Naeser et al. (2011) have reported in humans that chronic mTBI cases demonstrate improved cognitive function after PBM that is associated with increased ATP. In a recent study on major depression treatment, Schiffer et al. (2009) have shown that PBM increases regional cerebral blood flow in the contra-lesional frontal lobes (power density: 7.5 mW/cm<sup>2</sup>). It also increases cellular respiration and oxygenation of hypoxic cells (Mi et al. 2004a and b).

## 5 Conclusions

Research into photobiomodulation is revealing the beneficial effects of light therapy for a rapidly expanding list of medical conditions and illnesses. As it becomes more widely accepted by the mainstream medicine, its mechanism of action and the biophysics appear to be poorly understood. Importantly, therapeutic benefits of photobiomodulation, using red lasers, extend far beyond superficial applications.

**Acknowledgments** The authors acknowledge the editorial assistance of Dr. Carl S. Hornfeldt.

**Competing Interests** S.S. is president of the Erchonia Corporation in Melbourne, Florida; G.L. has no fiduciary relationship with any manufacturer or marketer of therapeutic laser equipment.

## References

- Adamskaya N, Dungal P, Mittermayr R, Hartinger J, Feichtinger G, Wassermann K, Redl H, van Griensven M (2011) Light therapy by blue LED improves wound healing in an excision model in rats. *Injury* 42:917–921
- Anders JJ, Lanzafame RJ, Arany PR (2015) Low-level light/laser therapy *versus* photobiomodulation therapy. *Photomed Laser Surg* 33:183–184
- Anderson RR, Parrish JA (1983) Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. *Science* 220:524–527
- Aragona SE, Grassi FR, Nardi G, Lotti J, Mereghetti G, Canavesi E, Equizi E, Puccio AM, Lotti T (2017) Photobiomodulation with polarized light in the treatment of cutaneous and mucosal ulcerative lesions. *J Biol Regul Homeost Agents* 31(2 Suppl 2):213–218
- Arany PR (2016) Craniofacial wound healing with photobiomodulation therapy: new insights and current challenges. *J Dent Res* 95:977–984
- Avci P, Gupta A, Sadasivam M, Vecchio D, Pam Z, Pam N, Hamblin MR (2013) Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. *Semin Cutan Med Surg* 32:41–52
- Avci P, Gupta GK, Clark J, Wikonkal N, Hamblin MR (2014) Low-level laser (light) therapy (LLLT) for treatment of hair loss. *Lasers Surg Med* 46:144–151
- Avram MM, Harry RS (2009) Cryolipolysis for subcutaneous fat layer reduction. *Lasers Surg Med* 41:703–708
- Basso FG, Oliveira CF, Fontana A, Kurachi C, Bagnato VS, Spolidório DM, Hebling J, de Souza Costa CA (2011) In vitro effect of low-level laser therapy on typical oral microbial biofilms. *Braz Dent J* 22:502–510
- Berman MH, Halper JP, Nichols TW, Jarrett H, Lundy A, Huang JH (2017) Photobiomodulation with near infrared light helmet in a pilot, placebo-controlled clinical trial in dementia patients testing memory and cognition. *J Neurol Neurosci* 8:176
- Biermann K, Montironi R, Lopez-Beltran A, Zhang S, Cheng L (2010) Histopathological findings after treatment of prostate cancer using high-intensity focused ultrasound (HIFU). *Prostate* 70:1196–1200
- Bjordal JM, Couppé C, Chow RT, Tunér J, Ljunggren EA (2003) A systematic review of low level laser therapy with location-specific doses for pain from chronic joint disorders. *Aust J Physiother* 49:107–116
- Bjordal JM, Bensadoun RJ, Tunér J, Frigo L, Gjerde K, Lopes-Martins RA (2011) A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. *Support Care Cancer* 19:1069–1077

- Burger E, Mendes AC, Bani GM, Brigagão MR, Santos GB, Malaquias LC, Chavasco JK, Verinaud LM, de Camargo ZP, Hamblin MR, Sperandio FF (2015) Low-level laser therapy to the mouse femur enhances the fungicidal response of neutrophils against *Paracoccidioides brasiliensis*. *PLoS Negl Trop Dis* 9 (2):e0003541
- Burks SR, Ziadloo A, Hancock HA, Chaudhry A, Dean DD, Lewis BK, Frenkel V, Frank JA (2011) Investigation of cellular and molecular responses to pulsed focused ultrasound in a mouse model. *PLoS One* 6 (9):e24730
- Carney C, Cantrell W, Warner J, Elewski B (2013) Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser. *J Am Acad Dermatol* 69:578–582
- Cassano P, Petrie SR, Hamblin MR, Henderson TA, Iosifescu DV (2016) Review of transcranial photobiomodulation for major depressive disorder: targeting brain metabolism, inflammation, oxidative stress, and neurogenesis. *Neurophotonics* 3:031404
- Cordeira CD, Lima Brigagão MR, Carli ML, de Souza Ferreira C, de Oliveira Isac Moraes G, Hadad H, Costa Hanemann JA, Hamblin MR, Sperandio FF (2016) Low-level laser therapy stimulates the oxidative burst in human neutrophils and increases their fungicidal capacity. *J Biophotonics* 9:1180–1188
- Chow RT, Johnson MI, Lopes-Martins RA, Bjordal JM (2009) Efficacy of low-level laser therapy in the management of neck pain: a systemic review and meta-analysis of randomized placebo or active-treatment controlled trials. *Lancet* 374:1897–1908
- Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR (2012) The nuts and bolts of low-level laser (light) therapy. *Ann Biomed Eng* 40:516–533
- Cicerone K, Levin H, Malec J, Stuss D, Whyte J (2006) Cognitive rehabilitation interventions for executive function: moving from bench to bedside in patients with traumatic brain injury. *J Cogn Neurosci* 18:1212–1222
- Cotler HB, Chow RT, Hamblin MR, Carroll J (2015) The use of low level laser therapy (LLL) for musculoskeletal pain. *MOJ Orthop Rheumatol* 2(5):pii 00068
- de Freitas LF, Hamblin MR (2016) Proposed mechanisms of photobiomodulation or low-level light therapy. *IEEE J Sel Top Quantum Electron* 22:7000417
- de Lima FM, Aimbire F, Miranda H, Vieira RP, deOliveira AP, Albertini R (2014) Low-level laser therapy attenuates the myeloperoxidase activity and inflammatory mediator generation in lung inflammation induced by gut ischemia and reperfusion: a dose-response study. *J Lasers Med Sci* 5:63–70
- de Oliveira VL, Silva JA Jr, Serra AJ, Pallota RC, da Silva EA, de Farias Marques AC, Feliciano RD, Marcos RL, Leal-Junior EC, de Carvalho PT (2017) Photobiomodulation therapy in the modulation of inflammatory mediators and bradykinin receptors in an experimental model of acute osteoarthritis. *Lasers Med Sci* 32:87–94
- DeTaboada L, Ilic S, Leichter-Martha S, Oron U, Oron A, Streeter J (2006) Transcranial application of low-energy laser irradiation improves neurological deficits in rats following acute stroke. *Lasers Surg Med* 38:70–73
- Farivar S, Malekshahi T, Shiari R (2014) Biological effects of low level laser therapy. *J Lasers Med Sci* 5:58–62
- Gross AR, Dziengo S, Boers O, Goldsmith CH, Graham N, Lilge L, Burnie S, White R (2013) Low level laser therapy (LLL) for neck pain: a systematic review and meta-regression. *Open Orthop J* 7:396–419
- Grover F Jr, Weston J, Weston M (2017) Acute effects of near infrared light therapy on brain state in healthy subjects as quantified by qEEG measures. *Photomed Laser Surg* 35:136–141
- Hamblin MR (2016) Shining light on the head: photobiomodulation for brain disorders. *BBA Clin* 6:113–124
- Hamblin MR (2017) Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. *AIMS Biophys* 4:337–361
- Hanczyc P, Norden B, Samoc M (2012) Two-photon absorption of metal-organic DNA-probes. *Dalton Trans* 41:3123–3125
- Harris SE, Field JE, Imamoglu A (1990) Nonlinear optical processes using electromagnetically induced transparency. *Phys Rev Lett* 64:1107–1110
- Hawkins DH, Abrahamse H (2006) The role of laser fluence in cell viability, proliferation, and membrane integrity of wounded human skin fibroblasts following helium-neon laser irradiation. *Lasers Surg Med* 38:74–83
- Heidari M, Paknejad M, Jamali R, Nokhbatolfighahaei H, Fekrazad R, Moslemi N (2017) Effect of laser photobiomodulation on wound healing and postoperative pain following free gingival graft: a split-mouth triple-blind randomized controlled clinical trial. *J Photochem Photobiol B* 172:109–114
- Helou J, Maatouk I, Hajjar MA, Moutran R (2016) Evaluation of Nd:YAG laser device efficacy on onychomycosis: a case series of 30 patients. *Mycoses* 59:7–11
- Hoge CW, McGurk D, Thomas JL, Cox AL, Engel CC, Castro CA (2008) Mild traumatic brain injury in U.S. soldiers returning from Iraq. *N Engl J Med* 358:453–463
- Holanda VM, Chavantes MC, Wu X, Anders JJ (2017) The mechanistic basis for photobiomodulation therapy of neuropathic pain by near infrared laser light. *Lasers Surg Med* 49:516–524
- Holmström KM, Finkel T (2014) Cellular mechanisms and physiological consequences of redox-dependent signalling. *Rev Mol Cell Biol* 15:411–421
- Hsieh YL, Cheng YJ, Huang FC, Yang CC (2014) The fluence effects of low-level laser therapy on inflammation, fibroblast-like synoviocytes, and synovial apoptosis in rats with adjuvant-induced arthritis. *Photomed Laser Surg* 32:669–677

- Huang YY, Chen AC, Carroll JD, Hamblin MR (2009) Biphasic dose response in low level light therapy. *Dose Response* 7:358–383
- Huang Z, Ma J, Chen J, Shen B, Pei F, Kraus VB (2015) The effectiveness of low-level laser therapy for non-specific chronic low back pain, a systematic review and meta-analysis. *Arthritis Res Ther* 17:360
- Ip D, Fu NY (2015) Two-year follow-up of low-level laser therapy for elderly with painful adhesive capsulitis of the shoulder. *J Pain Res* 8:247–252
- Jackson RF, Dedo DD, Roche GC, Turok DI, Maloney RJ (2009) Low-level laser therapy as a non-invasive approach for body contouring, a randomized, controlled study. *Lasers Surg Med* 41:799–809
- Jackson RF, Roche GC, Wisler K (2010) Reduction in cholesterol and triglyceride serum levels following low-level laser irradiation: a noncontrolled, nonrandomized pilot study. *Am J Cosmet Surg* 27:177–184
- Jackson RF, Stern FA, Neira R, Ortiz-Neira CL, Maloney J (2012) Application of low-level laser therapy for non-invasive body contouring. *Lasers Surg Med* 44:211–217
- Jackson RF, Roche GC, Shanks SC (2013) A double-blind, placebo-controlled randomized trial evaluating the ability of low-level laser therapy to improve the appearance of cellulite. *Lasers Surg Med* 45:141–147
- Janzadeh A, Nasirinezhad F, Masoumpoor M, Jameie SB, Hayat P (2016) Photobiomodulation therapy reduces apoptotic factors and increases glutathione levels in a neuropathic pain model. *Lasers Med Sci* 31:1863–1869
- Karu T (2013) Is it time to consider photobiomodulation as a drug equivalent? *Photomed Laser Surg* 31:189–191
- Karu TI, Afanasyeva NI (1995) Cytochrome C oxidase as primary photoacceptor for cultured cells in visible and near IR regions. *Doklady Akad Nauk (Moscow)* 342:693–695
- Kuffler DP (2016) Photobiomodulation in promoting wound healing: a review. *Regen Med* 11:107–122
- Lampf Y, Zivin JA, Fisher M, Lew R, Welin L, Dahlof B, Borenstein P, Andersson B, Perez J, Caparo C, Ilic S, Oron U (2007) Infrared laser therapy for ischemic stroke, a new treatment strategy: results of the NeuroThera effectiveness and safety Trial-1 (NEST-1). *Stroke* 38:1843–1849
- Lapchak PA (2010) Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science. *Ann Med* 42:576–586
- Lapchak PA, DeTaboada L (2010) Transcranial near infrared laser treatment (NILT) increases cortical adenosine-5'-triphosphate (ATP) content following embolic strokes in rabbits. *Brain Res* 1306:100–105
- Litscher D, Litscher G (2013) Laser therapy and stroke: quantification of methodological requirements in consideration of yellow laser. *Int J Photoen* 2013:575798. <https://doi.org/10.1155/2013/575798>
- Lu S, Zhang J, Liang Y, Li X, Cai W, Xi L (2016) The efficacy and prognostic factors for long pulse neodymium: yttrium-aluminum-garnet laser treatment on onychomycosis: a pilot study. *Ann Dermatol* 28:406–408
- Luo Y, Norman P, Macak P, Agren H (2000) Solvent-induced two-photon absorption of a push-pull molecule. *J Phys Chem A* 104:4718–4722
- Maksimovich IV (2016) Brain disorders and therapy. *Brain* 5:1000209
- Martins DF, Turnes BL, Cidral-Filho FJ, Bobinski F, Rosas RF, Danielski LG, Petronilho F, Santos AR (2016) Light-emitting diode therapy reduces persistent inflammatory pain: role of interleukin 10 and antioxidant enzymes. *Neuroscience* 324:485–495
- Maver-Biscanin M, Mravak-Stipetic VJ (2005) Effect of low-level laser therapy on *Candida albicans* growth in patients with denture stomatitis. *Photomed Laser Surg* 23:328–332
- McRae E, Boris J (2013) Independent evaluation of low-level laser therapy at 635 nm for non-invasive body contouring of the waist, hips, and thighs. *Lasers Surg Med* 45:1–7
- Meng C, He Z, Xing D (2013) Low-level laser therapy rescues dendrite atrophy via upregulating BDNF expression: implications for Alzheimer's disease. *J Neurosci* 33:13505–13517
- Mester E, Jászvágyi-Nagy E (1971) Biological effects of laser radiation. *Radiobiol Radiother (Berl)* 12:377–385
- Mi XQ, Chen JY, Liang ZJ, Zhou LW (2004a) *In vitro* effects of helium–neon laser irradiation on human blood: blood viscosity and deformability of erythrocytes. *Photomed Laser Surg* 22:477–482
- Mi XQ, Chen JY, Cen Y, Liang ZJ, Zhou LW (2004b) A comparative study of 632.8 and 532 nm laser irradiation on some rheological factors in human blood *in vitro*. *J Photochem Photobiol B* 74:7–12
- Moges H, Wu X, McCoy J, Vasconcelos OM, Bryant H, Grunberg NE, Anders JJ (2011) Effect of 810 nm light on nerve regeneration after autograft repair of severely injured rat median nerve. *Lasers Surg Med* 43:901–906
- Moon SH, Hur H, Oh YJ, Choi KH, Kim JE, Ko JY, Ro YS (2014) Treatment of onychomycosis with a 1,064-nm long-pulsed Nd:YAG laser. *J Cosmet Laser Ther* 16:165–167
- Moreira MS, Velasco IT, Ferreira LS, Ariga SK, Barbeiro DF, Meneguzzo DT, Abatepaulo F, Marques MM (2009) Effect of phototherapy with low intensity laser on local and systemic immunomodulation following focal brain damage in rat. *J Photochem Photobiol B* 97:145–151
- Moro C, Massri NE, Torres N, Ratel D, De Jaeger X, Chabrol C, Johnstone D (2014) Photobiomodulation inside the brain: a novel method of applying near-infrared light intracranially and its impact on dopaminergic cell survival in MPTP-treated mice. *J Neurosurg* 120:670–683
- Naeser MA, Saltmarche A, Krengel MH, Hamblin MR, Knight JA (2011) Improved cognitive function after

- transcranial, light-emitting diode treatments in chronic, traumatic brain injury: two case reports. *Photomed Laser Surg* 29:351–358
- Neira R, Arroyave J, Ramirez H, Ortiz CL, Solarte E, Sequeda F, Gutierrez MI (2002) Fat liquefaction: effect of low-level laser energy on adipose tissue. *Plast Reconstr Surg* 110:912–922
- Nenoff P, Grunewald S, Paasch U (2014) Laser therapy of onychomycosis. *J Dtsch Dermatol Ges* 12:33–38
- Nestor MS, Zarraga MB, Park H (2012) Effect of 635nm low-level laser therapy on upper arm circumference reduction: a double-blind, randomized, sham-controlled trial. *J Clin Aesthet Dermatol* 5:42–48
- Nogi SN, Mukherjee P, Ghajar J, Johnson C, Kolster RA, Sarkar R, Lee H, Meeker M, Zimmerman RD, Manley GT, McCandliss BD (2008) Extent of microstructural white matter injury in postconcussive syndrome correlates with impaired cognitive reaction time: a 3T diffusion tensor imaging study of mild traumatic brain injury. *AJNR Am J Neuroradiol* 29:967–973
- Noguchi H, Miyata K, Sugita T, Hiruma M, Hiruma M (2013) Treatment of onychomycosis using a 1064nm Nd:YAG laser. *Med Mycol J* 54:333–339
- Olesiak-Banska J, Hanczyc P, Matczyszyn K, Norden B, Samoc M (2012) Nonlinear absorption spectra of ethidium and ethidium homodimer. *Chem Phys* 404:33–35
- Oron A, Oron U, Chen J, Eilam A, Zhang C, Sadeh M, Lampl Y, Streeter J, DeTaboada L, Chopp M (2006) Low-level laser therapy applied transcranially to rats after induction of stroke significantly reduces long-term neurological deficits. *Stroke* 37:2620–2624
- Oron A, Oron U, Streeter J, de Taboada L, Alexandrovich A, Trembovler V, Shohami E (2007) Low-level laser therapy applied transcranially to mice following traumatic brain injury significantly reduces long-term neurological deficits. *J Neurotrauma* 24:651–656
- Paasch U, Mock A, Grunewald S, Bodendorf MO, Kandler M, Seitz AT, Simon JC, Nenoff P (2013) Antifungal efficacy of lasers against dermatophytes and yeasts *in vitro*. *Int J Hyperth* 29:544–550
- Paasch U, Nenoff P, Seitz AT (2014) Heat profiles of laser-irradiated nails. *J Biomed Opt* 19(1):18001
- Pereira FC, Parisi JR, Maglioni CB, Machado GB, Barragán-Iglesias P, Silva JRT, Silva ML (2017) Antinociceptive effects of low-level laser therapy at 3 and 8 J/cm<sup>2</sup> in a rat model of postoperative pain: possible role of endogenous opioids. *Lasers Surg Med* 49:844–851
- Pérez-Moreno J, Clays K, Kuzyk MG (2008) A new dipole-free sum-over-states expression for the second hyperpolarizability. *J Chem Phys* 128:084109
- Pires de Sousa MV, Ferraresi C, Kawakubo M, Kaippert B, Yoshimura EM, Hamblin MR (2016) Transcranial low-level laser therapy (810 nm) temporarily inhibits peripheral nociception: photoneuromodulation of glutamate receptors, prostatic acid phosphatase, and adenosine triphosphate. *Neurophotonics* 3:015003
- Poulos SP, Hausman DB, Hausman GJ (2010) The development and endocrine functions of adipose tissue. *Mol Cell Endocrinol* 323:20–34
- Prianti AC Jr, Silva JA Jr, Dos Santos RF, Rosseti IB, Costa MS (2014) Low-level laser therapy (LLLT) reduces the COX-2 mRNA expression in both subplantar and total brain tissues in the model of peripheral inflammation induced by administration of carrageenan. *Lasers Med Sci* 29:397–1403
- Roche GC, Murphy DJ, Berry TS, Shanks S (2016) Low-level laser therapy for the treatment of chronic neck and shoulder pain. *Funct Neurol Rehabil Ergon* 6:97–104
- Roche GC, Shanks S, Jackson RF, Holsey LJ (2017) Low-level laser therapy for reducing the hip, waist, and upper abdomen circumference of individuals with obesity. *Photomed Laser Surg* 35:142–149
- Rojas JC, Gonzalez-Lima F (2013) Neurological and psychological applications of transcranial lasers and LEDs. *Biochem Pharmacol* 86:447–457
- Rushdi TA (2010) Effect of low-level laser therapy on cholesterol and triglyceride serum levels in ICU patients: a controlled, randomized study. *EJCTA* 4:95–99
- Salehpour F, Rasta SH (2017) The potential of transcranial photobiomodulation therapy for treatment of major depressive disorder. *Rev Neurosci* 28:441–453
- Santana-Blank L, Rodríguez-Santana E, Santana-Rodríguez KE, Reyes H (2016) Quantum leap in photobiomodulation therapy ushers in a new generation of light-based treatments for cancer and other complex diseases: perspective and mini-review. *Photomed Laser Surg* 34:93–101
- Scherman M, Mishina OS, Lombardi P, Giacobino E, Laurat J (2012) Enhancing electromagnetically-induced transparency in a multilevel broadened medium. *Opt Express* 20:4346–4351
- Schiffer F, Johnston AL, Ravichandran C, Polcari A, Teicher MH, Webb RH, Hamblin MR (2009) Psychological benefits 2 and 4 weeks after a single treatment with NIR light to the forehead: a pilot study of 10 patients with major depression and anxiety. *Behav Brain Funct* 5:46
- Scwingel AR, Barcessat AR, Núñez SC, Ribeiro MS (2012) Antimicrobial photodynamic therapy in the treatment of oral candidiasis in HIV-infected patients. *Photomed Laser Surg* 30:429–432
- Seyedmousavi S, Hashemi SJ, Rezaie S, Fateh M, Djavid GE, Zibafar E, Morsali F, Zand N, Alinaghizadeh M, Ataie-Fashtami L (2014) Effects of low-level laser irradiation on the pathogenicity of *Candida albicans*: *in vitro* and *in vivo* study. *Photomed Laser Surg* 32:322–329
- Shaw VE, Spana S, Ashkan K, Benabid AL, Stone J, Baker GE, Mitrofanis J (2010) Neuroprotection in midbrain dopaminergic cells in MPTP-treated mice

- after near-infrared light treatment. *J Comp Neurol* 518:25–40
- Solarte E, Isaza C, Criollo W, Rebolledo AF, Arroyave J, Ramirez H, Neira R (2003) *In vitro* effects of 635 nm low intensity diode laser irradiation on the fat distribution of one adipose cell. *Proceedings SPIE, 19th Congress of the International Commission for Optics: Optics for the Quality of Life* 4829:961. <https://doi.org/10.1117/12.527513>
- Solmaz H, Ulgen Y, Gulsoy M (2017) Photobiomodulation of wound healing via visible and infrared laser irradiation. *Lasers Med Sci* 32:903–910
- Stemer AB, Huisa BN, Zivin JA (2010) The evolution of transcranial laser therapy for acute ischemic stroke, including a pooled analysis of NEST-1 and NEST-2. *Curr Cardiol Rep* 12:29–33
- Suarez DP, Roche GC, Jackson RF (2014) A double-blind, sham-controlled study demonstrating the effectiveness of low-level laser therapy using a 532-nm green diode for contouring the waist, hips, and thighs. *Am J Cosmet Surg* 31:34–41
- Taber KH, Warden DL, Hurley RA (2006) Blast-related traumatic brain injury: what is known? *J Neuropsychiatry Clin Neurosci* 18:141–145
- Takahashi H, Okuni I, Ushigome N, Harada T, Tsuruoka H, Ohshiro T, Sekiguchi M, Musya Y (2012) Low level laser therapy for patients with cervical disk hernia. *Laser Ther* 21:193–197
- Tedford CE, DeLapp S, Jacques S, Anders J (2015) Quantitative analysis of transcranial and intraparenchymal light penetration in human cadaver brain tissue. *Lasers Surg Med* 47:312–322
- Thornfeldt CR, Thaxton PM, Hornfeldt CS (2016) A six-week low-level laser therapy protocol is effective for reducing waist, hip, thigh, and upper abdomen circumference. *J Clin Aesthet Dermatol* 9:31–35
- Wang L, Hu L, Grygorczyk R, Shen X, Schwarz W (2015) Modulation of extracellular ATP content of mast cells and DRG neurons by irradiation: studies on underlying mechanism of low-level-laser therapy. *Med Inf* 2015:630361
- Wang X, Tian F, Soni SS, Gonzalez-Lima F, Liu H (2016) Interplay between up-regulation of cytochrome-c-oxidase and hemoglobin oxygenation induced by near-infrared laser. *Sci Rep* 6:30540
- Weis S, Rivière R, Deléglise S, Gavartin E, Arcizet O, Schliesser A, Kippenberg TJ (2010) Optomechanically induced transparency. *Science* 330:1520–1523
- Wu Q, Xuan W, Ando T, Xu T, Huang L, Huang YY, Dai T, Dhital S, Sharma SK, Whalen MJ, Hamblin MR (2012) Low-level laser therapy for closed-head traumatic brain injury in mice: effect of different wavelengths. *Lasers Surg Med* 44:218–226
- Yadav A, Gupta A (2017) Noninvasive red and near-infrared wavelength-induced photobiomodulation: promoting impaired cutaneous wound healing. *Photodermatol Photoimmunol Photomed* 33:4–13
- Zang K, Sullivan S, Shanks S (2017) A retrospective study of non-thermal laser therapy for the treatment of toe nail onychomycosis. *J Clin Aesthet Dermatol* 10:24–30
- Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing JR (1997) A rat model of focal embolic cerebral ischemia. *Brain Res* 766:83–92
- Zivin JA, Albers GW, Bornstein N, Chippendale T, Dahlof B, Devlin T, Fisher M, Hacke W, Holt W, Ilic S, Kasner S, Lew R, Nash M, Perez J, Rymer M, Schellinger P, Schneider D, Schwab S, Veltkamp R, Walker M, Streeter J, NeuroThera Effectiveness and Safety Trial-2 Investigators (2009) Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. *Stroke* 40:1359–1364